Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFURO: Inhaled furosemide and oral levodropropizine for dyspnea in advanced lung disease
2024-514672-41-00Phase 2Authorised
- Sponsor
- Fakultní nemocnice Hradec Králové
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of furosemide and levodropropizine in Dyspnoea (SOB), asthma, chronic obstructive pulmonary disease (COPD) and 4 more, sponsored by Fakultní nemocnice Hradec Králové. Primary endpoint: Safety and tolerability of inhaled furosemide. Planned start Aug 2024; status: authorised.
02
Drugs
furosemidelevodropropizine
03
Conditions
Dyspnoea (SOB)asthmachronic obstructive pulmonary disease (COPD)interstitial lung disease (ILD)bronchial carcinoma
Beyond the preview
Go deeper on 2024-514672-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514672-41-00.